34 results about "Mental disease" patented technology

The present invention relates to a system and method for recommending health functional foods to elderly patients with geriatric chronic diseases. According to the present invention, a method for recommending health functional foods, performed by a system for recommending health functional foods, comprises the steps of: receiving, from a target patient with a geriatric chronic disease, response data obtained from responses to a medical inquiry form or questionnaire; performing natural language processing on the response data; inputting the natural-language-processed response data into a first learning model to classify a mental disorder and a severity level of the target patient; receiving personal information and EMR data of the target patient; and inputting the personal information, EMR data , and information on the mental disorder and severity level of the target patient into a second learning model to recommend one or more health functional foods to the target patient.

Disclosed are ready to use non-aqueous solutions of lamotrigine. The lamotrigine is dissolved in a solvent, wherein the solvent comprises propylene glycol and optionally at least one co-solvent, and wherein if water is present in the ready to use non-aqueous solution, the water is not at least one co-solvent. Also disclosed are methods for treating a neurological disorder or a mental disorder by administering the ready to use non-aqueous solutions of lamotrigine, processes for preparing ready to use non-aqueous solutions of lamotrigine, and kits containing lamotrigine to prepare ready to use non-aqueous solutions of lamotrigine.

This invention proposes a sanitary diaper that, through the combination of a waist-tightening structure and a concealed structure, reduces the likelihood of patients unfastening the diaper themselves. Simultaneously, the support unit ensures a tight fit, reducing the probability of the diaper loosening or leakage due to excessive patient movement. This meets the special needs of patients with mental illnesses and effectively solves the problem of diapers being easily removed or loosened, reducing the risk of fecal contamination. Specifically, the concealed structure design prevents patients from directly contacting the tightening structure, while the elastic support of the support unit adapts to potentially large movements by the patient, ensuring the stability of the diaper.

This invention discloses a method for identifying mental illnesses combining electronic medical records and electroencephalogram (EEG) signals, comprising: acquiring electronic medical records and the corresponding patient's raw EEG signals; labeling patients based on disease type, and combining the labels, electronic medical records, and raw EEG signals into a dataset; constructing an initial model based on a large language model and a prior mental illness knowledge base, wherein the initial model includes an agent scheduling module, a data processing module, and a prediction module; and training the initial model using the dataset to obtain a multimodal predictive agent model for mental illnesses used to generate medical reports. The method provided by this invention enables multi-scale, multi-channel, and multi-feature exploratory analysis of EEG signals at any specified time slice, and jointly reasoning with medical record features and a mental illness knowledge base to generate structured diagnostic conclusions and interpretable reports.

A method for treating a neurological or psychiatric disorder in a subject is provided, including sequentially delivering low-intensity focused ultrasound (LIFU) neuromodulation to a plurality of brain targets while measuring one or more disease-related metrics, selecting, based on the measured metrics, a subset of brain targets exhibiting improvement satisfying a predefined selection criterion, and delivering high-intensity focused ultrasound (HIFU or sustained LIFU) neuromodulation to the selected subset to produce durable reduction of one or more disease signs or symptoms.

This invention belongs to the field of SNP site detection technology for guiding the use of second-generation antipsychotic drugs. Specifically, it relates to primer and probe combinations and applications for SNP site detection to guide personalized medication of second-generation antipsychotic drugs. The SNP site is rs17782313. The primer and probe combination includes an upstream primer SEQ ID NO:1 that specifically amplifies the wild-type T allele, an upstream primer SEQ ID NO:2 that specifically amplifies the mutant C allele, a universal downstream primer SEQ ID NO:3, a wild-type probe SEQ ID NO:4, and a mutant probe SEQ ID NO:5. This invention assesses the genetic risk of weight gain and metabolic disorders in patients with mental illness after taking second-generation antipsychotic drugs such as risperidone, quetiapine, amisulpride, and paliperidone through rapid and accurate genotyping. It features high specificity, high accuracy, speed, simplicity, and controllable cost, and can achieve rapid single-tube genotyping, providing key genetic evidence for the clinical development of personalized medication regimens.

A sterol-based compound of formula (I) for its use in preventing, ameliorating and / or treating a mitochondrial deficiency-related pathology chosen from the group consisting of autism, spinal cord injury, multiple sclerosis, epilepsy, migraine, alcohol-related mental pathologies, ataxia, neuropathies, smoking-related cerebral and pulmonary disorders, MERRF syndrome and NARP syndrome. A pharmaceutical composition comprising at least one compound of formula (I).

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

This invention provides a method for estimating neuropsychological activity that can accurately predict developmental disorders, mental illnesses, and other conditions. [Solution] Time-series data of the subject's pupil diameter and time-series data of the subject's eye movements are obtained. The time-averaged value of the pupil diameter is calculated from the time-series data of the pupil diameter, and the complexity of eye movements for each time scale is quantified from the time-series data of eye movements. Based on the time-averaged value of the pupil diameter and the complexity of eye movements, the subject's neuropsychiatric activity is estimated.

1. Name of the designed product: Potentiometer (medical event-related). 2. Use of the designed product: to assist in the diagnosis and evaluation of nervous system and mental diseases by recording and analyzing the electrical signals produced by the brain in response to specific stimuli. 3. Design points of the designed product: in shape. 4. Picture or photo that best indicates the design points: perspective view 1.

The present disclosure provides phenylalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenylalkylamine compounds are provided. Also disclosed herein are methods of treating a psychiatric disease or disorder, which include administering to a patient in need a therapeutically effective amount of any one of the therapeutic compounds described herein or a pharmaceutical composition containing the therapeutic compound.

A mental illness diagnosis system includes a first learning unit configured to cause a mental illness diagnosis algorithm to be learned to classify exosome SERS signals included in input signal maps into 0 and 1 by inputting a first signal map acquired by using exosomes acquired from a normal person and a second signal map acquired by using exosomes acquired from a mental illness patient to the mental illness diagnosis algorithm, a signal acquisition unit configured to drop exosomes acquired from a measurement target person onto a chip including multiple dot arrays and acquire a signal map including multiple exosome SERS signals from the chip, and a diagnosis unit configured to input the acquired signal map to the mental illness diagnosis algorithm for which learning is completed.

6,7-dihydrothiazolo[5,4-c]pyridine, substituted at position 5 with 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one or flu[3,4-b]pyridine-5(7H)-one, is a positive allosteric modulator of the muscarinic acetylcholine receptor M4 (mAChR M4) and may be used to treat neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.

This disclosure relates to dosage forms comprising: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of dextromethorphan; and 2) about 25-35 mg, about 29-31 mg, about 30 mg, about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. In some embodiments, a dosage form as described herein is free of a Compound I and Compound II. In some embodiments, a dosage form may contain 0.5 ng to 750 ng of Compound I, 0.5 ng to 750 ng of Compound II, or a combination thereof. These dosage forms may be used to treat various neurological and psychiatric conditions, including major depressive disorder, agitation associated with Alzheimer's disease, and nicotine addiction.

Systems and methods for providing treatment for psychiatric conditions are disclosed. Preferred systems include programs stored in a memory and configured to be executed by processors to treat a subject for a psychiatric condition. The programs include instructions for conducting a therapy session, which includes a plurality of sequential turns. Each turn includes: (i) displaying, for a predetermined focal point indicator display time period and thereafter terminating the displaying of, a focal point indicator at a focal point indicator location in a display area of a display; (ii) after terminating the display of the focal point indicator, displaying, together for a predetermined stimulus display time period and thereafter terminating the display of, first and second stimulus images at respective first and second stimulus image locations in the display area, the first and second stimulus images being associated with respective first and second stimuli, the stimulus image locations being of equal prominence in relation to the focal point indicator location; (iii) after terminating the display of the stimulus images, displaying in connection with the first stimulus image location a response invitation indicator; (iv) receiving a user input in response to the display of the response invitation indicator; (v) determining at least one user input aspect of the user input related to the display of the response invitation indicator; and (vi) when the at least one user input aspect has at least one desired characteristic, implementing a user incentive to modify the user input aspect for a subsequent turn.

The present invention relates to a diazaheterocyclic derivative of a pyridoaryl group having Kappa receptor antagonistic activity. Specifically, the present invention relates to a compound represented by general formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable salt of the stereoisomer. The present invention further relates to a pharmaceutical composition containing the compound and a preparation method therefor, a method for treating diseases related to Kappa receptor antagonistic activity, such as depression, depression with anhedonia, bipolar disorder, anxiety, and other mental diseases, and a use. The definition of each substituent in general formula (I) is the same as that in the description.

The utility model provides a kind of sickbed protection frame and protective sickbed, wherein sickbed protection frame is through the protection framework structure that can be unfolded, effectively solve the safety protection problem of open area above sickbed in mental illness medical environment;Compared with the fixed height guardrail of tradition, protection framework can completely cover the open space above sickbed after unfolding, prevent other patients from the open space to implement harmful behavior, to reduce the occurrence of injury accident;The design of folding and unfolding of protection framework both guarantees protection effect, and it is convenient for medical staff to operate, so as to fold protection framework without protection;The fixing structure of base frame ensures the stability of protection frame during use, avoids displacement due to patient collision, and makes the utility model can be installed or removed according to medical environment;Protective sickbed includes aforementioned sickbed protection frame, so that sickbed obtains protection function when protection framework unfolds, to reduce the occurrence of injury accident.

To enable support in the differential diagnosis of heart disease. [Solution] An information processing system comprising: an answer input unit that receives input from a patient's answers to questions for differentiating mental illnesses; a video image acquisition unit that acquires video images of the patient; a biological response detection unit that analyzes the video images to detect changes in the patient's biological responses; and an estimation unit that estimates the mental illness the patient is suffering from by providing the received answers and detected changes in biological responses to a learning model that has learned the answers, changes in biological responses, and mental illnesses.

The present invention relates to a method for mental illness diagnosis and drug recommendation using a mental health questionnaire. The method may provide highly reliable and accurate mental illness diagnosis information and information on medication based on a large amount of data, thereby improving medical quality and reducing medical costs.

A method for treating a neurological or psychiatric disorder in a subject is provided, including sequentially delivering low-intensity focused ultrasound (LIFU) neuromodulation to a plurality of brain targets while measuring one or more disease-related metrics, selecting, based on the measured metrics, a subset of brain targets exhibiting improvement satisfying a predefined selection criterion, and delivering high-intensity focused ultrasound (HIFU or sustained LIFU) neuromodulation to the selected subset to produce durable reduction of one or more disease signs or symptoms.

Preparation and use of a tangerine peel polysaccharide and a composition thereof. Provided is use of a Citri reticulatae pericarpium crude polysaccharide and a characteristic component PCRCPI thereof in alleviating nerve injury, depression-like behaviors, and metabolism-related mental diseases; they can effectively ameliorate depression-like behaviors caused by HFD diet, restore the levels of neurotransmitters DA and 5-HT, and upregulate neuronal cell activity biomarkers DCX and Neun.

Provided are compounds of the Formula I, and salts and solvates thereof: (I) wherein R1, R2, R3, X1, X2, X3 and Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, pathological angiogenesis, an inflammatory disease or condition, a musculoskeletal disease or condition, an autoimmune disease, a haematological disease or condition, a neurological disease or condition, a psychiatric disorder, or a metabolic disorder.

The application discloses a two-dimensional objective detection device and method for quantifying subjective emotion of mice, which comprises a box body, the periphery and top of the box body are made of black acrylic material, the bottom is made of transparent material, the box body is sequentially provided with a runway A, a chamber a, a runway B and a chamber b along the length direction, beam type pressure sensors are arranged at the bottom of the runway A and the runway B and used for monitoring the walking speed, ground touch speed and ground touch pressure parameters of the mice in the runway; the probability of the mice obtaining food in the first chamber is changed, the walking speed, ground touch speed and ground touch pressure parameters of the mice in the runway are monitored, the emotional experience of the mice on the second runway is obtained according to the monitoring result, a fast and simple behavior paradigm is adopted to detect the subjective emotional experience of the mice in two dimensions, the emotional experience of the mice is more accurately measured in the dimensions of happiness and unhappiness and the degree of awakening, and a new idea is provided for the research on emotional and affective disorders in mental diseases.

The utility model discloses a kind of restraint chair for mental illness patient nursing, it is related to medical nursing technical field, including seat plate, the left side surface and right side surface of seat plate are all fixedly connected with connecting frame, further including angle adjusting assembly, leg restraint assembly, supporting plate and self-adapting adjusting assembly.The utility model is adjusted to the angle of leg placing plate and backrest by being set angle adjusting assembly, to be able to effectively promote the comfort of patient, by being set leg restraint assembly, the leg of patient can also be effectively bound and handled, to be able to further promote the restraint effect of device whole to patient, by being set self-adapting adjusting assembly, the hand restraint degree of patient can be self-adapting adjusted and handled according to the actual situation of patient on site, to avoid patient hand long time in relatively tight constraint, blood does not circulate, further promote the practicability of device whole.

Pharmaceutical compositions containing therapeutically effective amounts of psychoactive agents may be used to treat, manage, or prevent neurological disorders, mental illnesses and disorders, and other diseases and disorders. Through the delivery of these compounds, it may be possible to safely and effectively enable the subject to address undesirable symptoms of these diseases and disorders, and / or the diseases and disorders themselves. This invention relates to pharmaceutical compositions comprising compounds that are tryptamine derivatives.